Developer docs
API playgroundTry for free, no card

Search company profiles

Vera Therapeutics

Full company profile

uuid0000auh

Namestring
Vera Therapeutics
Legal namestring
Vera Therapeutics, Inc.
Websiteurl
veratx.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Vera Therapeutics is a clinical-stage biotechnology company founded in 2016 and listed on NASDAQ under the ticker VERA, headquartered in Brisbane, California (with a prior South San Francisco address still referenced in legal materials). The company focuses on developing biologic therapeutics for serious B-cell-mediated autoimmune diseases, with a primary emphasis on immune-mediated kidney disease and most notably IgA nephropathy (IgAN), the most common primary glomerular disease worldwide and one with no approved disease-modifying treatments. Its lead asset, atacicept, is an investigational soluble recombinant fusion protein containing the native human TACI receptor that binds both BAFF and APRIL cytokines, reducing B-cell survival signaling and autoantibody production. Atacicept was in-licensed worldwide from Ares Trading S.A., a Merck KGaA affiliate, and has been administered to more than 1,500 patients across multiple autoimmune indications. In November 2025 Vera submitted a Biologics License Application for atacicept in IgAN under the accelerated approval pathway; FDA granted Priority Review in January 2026 with a PDUFA target action date of July 7, 2026, and the asset also carries Breakthrough Therapy Designation.

The broader pipeline includes MAU868, a first-in-class monoclonal antibody neutralizing BK virus in kidney transplant recipients, and VT-109, a next-generation BAFF/APRIL fusion protein exclusively licensed from Stanford University. The ORIGIN Phase 2b/3 program supports the IgAN BLA (46% proteinuria reduction from baseline, 42% versus placebo) and ORIGIN Extend provides continued access; the PIONEER Phase 2 program is expanding atacicept into anti-PLA2R-positive primary membranous nephropathy, anti-nephrin-positive minimal change disease, and FSGS. Vera holds all global development and commercial rights to its pipeline.

The company is pre-revenue with no approved products. Once atacicept is approved, Vera intends to commercialize through specialty pharmacy distribution and direct-to-patient delivery of a self-administered once-weekly subcutaneous injection, supported by physician (nephrologist) education and market access capabilities. Reported FY2025 net loss was $299.6 million (versus $152.1 million in 2024), with $714.6 million in cash, equivalents, and marketable securities as of December 31, 2025, $596.8 million as of Q1 2026, and an up-to-$500 million credit facility from Oxford Finance LLC secured in June 2025. Capital has been raised via an approximately $80 million Series C, a $74.9 million February 2022 offering, a $250 million January 2024 offering, and a $261 million December 2025 offering. Aggressive hiring across 2025-2026 (including 89 inducement grants in April 2026 alone) and senior commercial hires such as Chief Commercial Officer Matt Skelton reflect pre-launch buildout for a potential mid-2026 U.S. commercial launch.

Short descriptiontext

Vera Therapeutics is a late-stage biotechnology company developing biologic therapeutics for B-cell-mediated autoimmune kidney diseases, primarily atacicept for IgA nephropathy, with a potential U.S. commercial launch in mid-2026 pending FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBrisbane, United States
HQ citystring
Brisbane
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologic therapeutics, autoimmune disease treatments, IgA nephropathy therapy, kidney disease drugs, monoclonal antibody drugs
Industry3 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologic Therapeutics for Autoimmune Kidney Disease
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Product Sales (pending approval)
TypeOne Time License
Description

Vera Therapeutics is pre-revenue with no approved products. The company expects potential U.S. commercial launch of atacicept in mid-2026 pending FDA approval. Once approved, revenue will be generated through product sales of atacicept for IgA nephropathy and potentially other indications.

ir.veratx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Pricing to be determined upon FDA approval
ModelOtherBilling cadenceMulti-year contract
Notes

No pricing information available as atacicept is still under FDA review with PDUFA date of July 7, 2026.

ir.veratx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vera Therapeutics develops investigational biologic therapeutics for serious immunological diseases, with a primary focus on IgA nephropathy (IgAN). Its lead product candidate, atacicept, is a recombinant fusion protein containing the human TACI receptor that binds and neutralizes both BAFF and APRIL cytokines, reducing B-cell mediated autoantibody production. The company is transitioning from clinical-stage to commercial-stage, targeting a 2026 U.S. launch of atacicept as a self-administered weekly subcutaneous injection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 46% statistically significant reduction in proteinuria from baseline (primary endpoint met in ORIGIN Phase 3)
+4 more records
Product overview1 text field

Vera Therapeutics is a late-stage biotechnology company developing transformative treatments for serious immunological diseases, with a focus on immune-mediated kidney disease. The company's product portfolio centers on three investigational therapies: atacicept (a dual BAFF/APRIL inhibitor fusion protein in Phase 3 for IgA nephropathy), MAU868 (a monoclonal antibody for BK virus in kidney transplant recipients), and VT-109 (a next-generation BAFF/APRIL inhibitor). The company operates clinical trial programs including ORIGIN (atacicept in IgAN) and PIONEER (atacicept in multiple glomerular diseases). Vera Therapeutics retains all global developmental and commercial rights to its pipeline candidates.

Product and service3 records
1Atacicept
CategoryBiologic Therapeutic
Description

Investigational soluble recombinant fusion protein containing the human TACI receptor that binds and neutralizes both BAFF and APRIL cytokines, reducing B-cell mediated autoantibody production. Self-administered as a subcutaneous once-weekly injection. Designed for adults with IgA nephropathy.

2MAU868
CategoryBiologic Therapeutic
Description

First-in-class investigational monoclonal antibody designed to neutralize BK virus (BKV) by binding to the virus and preventing it from attaching to and entering host cells. Targeting kidney transplant recipients at risk of BKV reactivation.

3VT-109
CategoryBiologic Therapeutic
Description

Novel, next-generation fusion protein targeting BAFF and APRIL cytokines with therapeutic potential across the spectrum of B-cell-mediated diseases. Licensed from Stanford University; Vera holds global development and commercial rights.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage biotech with Filspari (sparsentan) already approved for IgA nephropathy, the most direct competitor to atacicept in the same indication and prescriber base.

TypeDirect peer
Description

Markets Tarpeyo (budesonide delayed-release) for IgAN, competing in the same autoimmune nephrology specialty channel that Vera is preparing to enter.

TypeDirect peer
Description

Developing sibeprenlimab (anti-APRIL monoclonal antibody) for IgAN, representing a direct mechanism-adjacent competitor to atacicept's BAFF/APRIL dual blockade.

TypeDirect peer
Description

Acquired by Novartis, developing zigakibart (anti-APRIL) for IgAN. Now part of Novartis's nephrology pipeline, directly comparable in mechanism and indication.

TypeDirect peer
Description

Markets voclosporin (Lupkynis) for lupus nephritis, another immune-mediated glomerular disease; competes in overlapping nephrology specialty prescribing.

TypeEmerging player
Description

Commercial-stage biotech with Vyvgart (efgartigimod), an FcRn modulator for autoimmune disease. Comparable biologic modality and B-cell pathway targeting with similar commercial-stage inflection.

TypeBroad incumbent
Description

Co-markets Filspari with Travere in IgAN through ex-US partnership, making Vertex a direct strategic competitor in the same nephrology franchise.

TypeBroad incumbent
Description

Leader in autoimmune biologics with rituximab and obinutuzumab (anti-CD20 B-cell depleters) widely used off-label in IgAN and related nephropathies.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Major immunology franchise with Zeposia (ozanimod) and Sotyktu (deucravacitinib); potential competitor for autoimmune indications Vera may pursue.

TypeBroad incumbent
Description

Through Alexion, markets complement inhibitors (Soliris/Ultomiris) for rare kidney diseases including IgAN; established specialty nephrology commercial infrastructure and rare-disease expertise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vera Therapeutics

Biologic Therapeutics for Autoimmune Kidney Diseaseveratx.com

Vera Therapeutics is a late-stage biotechnology company developing biologic therapeutics for B-cell-mediated autoimmune kidney diseases, primarily atacicept for IgA nephropathy, with a potential U.S. commercial launch in mid-2026 pending FDA approval.

What Vera Therapeutics does

Vera Therapeutics is a clinical-stage biotechnology company founded in 2016 and listed on NASDAQ under the ticker VERA, headquartered in Brisbane, California (with a prior South San Francisco address still referenced in legal materials). The company focuses on developing biologic therapeutics for serious B-cell-mediated autoimmune diseases, with a primary emphasis on immune-mediated kidney disease and most notably IgA nephropathy (IgAN), the most common primary glomerular disease worldwide and one with no approved disease-modifying treatments. Its lead asset, atacicept, is an investigational soluble recombinant fusion protein containing the native human TACI receptor that binds both BAFF and APRIL cytokines, reducing B-cell survival signaling and autoantibody production. Atacicept was in-licensed worldwide from Ares Trading S.A., a Merck KGaA affiliate, and has been administered to more than 1,500 patients across multiple autoimmune indications. In November 2025 Vera submitted a Biologics License Application for atacicept in IgAN under the accelerated approval pathway; FDA granted Priority Review in January 2026 with a PDUFA target action date of July 7, 2026, and the asset also carries Breakthrough Therapy Designation.

The broader pipeline includes MAU868, a first-in-class monoclonal antibody neutralizing BK virus in kidney transplant recipients, and VT-109, a next-generation BAFF/APRIL fusion protein exclusively licensed from Stanford University. The ORIGIN Phase 2b/3 program supports the IgAN BLA (46% proteinuria reduction from baseline, 42% versus placebo) and ORIGIN Extend provides continued access; the PIONEER Phase 2 program is expanding atacicept into anti-PLA2R-positive primary membranous nephropathy, anti-nephrin-positive minimal change disease, and FSGS. Vera holds all global development and commercial rights to its pipeline.

The company is pre-revenue with no approved products. Once atacicept is approved, Vera intends to commercialize through specialty pharmacy distribution and direct-to-patient delivery of a self-administered once-weekly subcutaneous injection, supported by physician (nephrologist) education and market access capabilities. Reported FY2025 net loss was $299.6 million (versus $152.1 million in 2024), with $714.6 million in cash, equivalents, and marketable securities as of December 31, 2025, $596.8 million as of Q1 2026, and an up-to-$500 million credit facility from Oxford Finance LLC secured in June 2025. Capital has been raised via an approximately $80 million Series C, a $74.9 million February 2022 offering, a $250 million January 2024 offering, and a $261 million December 2025 offering. Aggressive hiring across 2025-2026 (including 89 inducement grants in April 2026 alone) and senior commercial hires such as Chief Commercial Officer Matt Skelton reflect pre-launch buildout for a potential mid-2026 U.S. commercial launch.

Vera Therapeutics firmographics

Firmographics
Name
Vera Therapeutics
Legal name
Vera Therapeutics, Inc.
Website
https://veratx.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
251–500 employees
Short description
Vera Therapeutics is a late-stage biotechnology company developing biologic therapeutics for B-cell-mediated autoimmune kidney diseases, primarily atacicept for IgA nephropathy, with a potential U.S. commercial launch in mid-2026 pending FDA approval.
Ownership category
akta.pro rank

Vera Therapeutics industry classification

Industry
Product category
Biologic Therapeutics for Autoimmune Kidney Disease
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Biologic therapeutics
  • Autoimmune disease treatments
  • IgA nephropathy therapy
  • Kidney disease drugs
  • Monoclonal antibody drugs

Where Vera Therapeutics is headquartered

Location

Headquarters

HQ city
Brisbane
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vera Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Product Sales (pending approval): Vera Therapeutics is pre-revenue with no approved products. The company expects potential U.S. commercial launch of atacicept in mid-2026 pending FDA approval. Once approved, revenue will be generated through product sales of atacicept for IgA nephropathy and potentially other indications.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPricing to be determined upon FDA approval

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Vera Therapeutics product offering

Product offering

Core offering

Vera Therapeutics develops investigational biologic therapeutics for serious immunological diseases, with a primary focus on IgA nephropathy (IgAN). Its lead product candidate, atacicept, is a recombinant fusion protein containing the human TACI receptor that binds and neutralizes both BAFF and APRIL cytokines, reducing B-cell mediated autoantibody production. The company is transitioning from clinical-stage to commercial-stage, targeting a 2026 U.S. launch of atacicept as a self-administered weekly subcutaneous injection.

Product overview

Vera Therapeutics is a late-stage biotechnology company developing transformative treatments for serious immunological diseases, with a focus on immune-mediated kidney disease. The company's product portfolio centers on three investigational therapies: atacicept (a dual BAFF/APRIL inhibitor fusion protein in Phase 3 for IgA nephropathy), MAU868 (a monoclonal antibody for BK virus in kidney transplant recipients), and VT-109 (a next-generation BAFF/APRIL inhibitor). The company operates clinical trial programs including ORIGIN (atacicept in IgAN) and PIONEER (atacicept in multiple glomerular diseases). Vera Therapeutics retains all global developmental and commercial rights to its pipeline candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • Atacicept Investigational soluble recombinant fusion protein containing the human TACI receptor that binds and neutralizes both BAFF and APRIL cytokines, reducing B-cell mediated autoantibody production. Self-administered as a subcutaneous once-weekly injection. Designed for adults with IgA nephropathy.
  • MAU868 First-in-class investigational monoclonal antibody designed to neutralize BK virus (BKV) by binding to the virus and preventing it from attaching to and entering host cells. Targeting kidney transplant recipients at risk of BKV reactivation.
  • VT-109 Novel, next-generation fusion protein targeting BAFF and APRIL cytokines with therapeutic potential across the spectrum of B-cell-mediated diseases. Licensed from Stanford University; Vera holds global development and commercial rights.

Quantifiable outcome

  • 46% statistically significant reduction in proteinuria from baseline (primary endpoint met in ORIGIN Phase 3)
  • +4 more outcomes

Companies that use Vera Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Vera Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vera Therapeutics partnerships and signals

Strategic signal

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Vera Therapeutics competitors and assessment

Company assessment

Direct peers

  • Travere Therapeutics: Commercial-stage biotech with Filspari (sparsentan) already approved for IgA nephropathy, the most direct competitor to atacicept in the same indication and prescriber base.
  • Calliditas Therapeutics: Markets Tarpeyo (budesonide delayed-release) for IgAN, competing in the same autoimmune nephrology specialty channel that Vera is preparing to enter.
  • Otsuka Pharmaceutical: Developing sibeprenlimab (anti-APRIL monoclonal antibody) for IgAN, representing a direct mechanism-adjacent competitor to atacicept's BAFF/APRIL dual blockade.
  • Chinook Therapeutics (Novartis): Acquired by Novartis, developing zigakibart (anti-APRIL) for IgAN. Now part of Novartis's nephrology pipeline, directly comparable in mechanism and indication.
  • Aurinia Pharmaceuticals: Markets voclosporin (Lupkynis) for lupus nephritis, another immune-mediated glomerular disease; competes in overlapping nephrology specialty prescribing.

Emerging players

  • argenx: Commercial-stage biotech with Vyvgart (efgartigimod), an FcRn modulator for autoimmune disease. Comparable biologic modality and B-cell pathway targeting with similar commercial-stage inflection.

Broad incumbents

  • Vertex Pharmaceuticals: Co-markets Filspari with Travere in IgAN through ex-US partnership, making Vertex a direct strategic competitor in the same nephrology franchise.
  • Roche / Genentech: Leader in autoimmune biologics with rituximab and obinutuzumab (anti-CD20 B-cell depleters) widely used off-label in IgAN and related nephropathies.
  • Bristol-Myers Squibb: Major immunology franchise with Zeposia (ozanimod) and Sotyktu (deucravacitinib); potential competitor for autoimmune indications Vera may pursue.
  • AstraZeneca / Alexion: Through Alexion, markets complement inhibitors (Soliris/Ultomiris) for rare kidney diseases including IgAN; established specialty nephrology commercial infrastructure and rare-disease expertise.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Vera Therapeutics social profiles

Digital presence

Vera Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vera Therapeutics leadership team

Management profile

Number of profiles

Profiles17 records

Vera Therapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vera Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vera Therapeutics

What does Vera Therapeutics do?

Vera Therapeutics develops investigational biologic therapeutics for serious immunological diseases, with a primary focus on IgA nephropathy (IgAN). Its lead product candidate, atacicept, is a recombinant fusion protein containing the human TACI receptor that binds and neutralizes both BAFF and APRIL cytokines, reducing B-cell mediated autoantibody production. The company is transitioning from clinical-stage to commercial-stage, targeting a 2026 U.S. launch of atacicept as a self-administered weekly subcutaneous injection.

Is Vera Therapeutics a public or private company?

Vera Therapeutics is a public company. It is classified as public and is currently operating.

When was Vera Therapeutics founded?

Vera Therapeutics was founded in 2016. It employs 251 to 500 people.

Where is Vera Therapeutics based?

Vera Therapeutics is headquartered in Brisbane, United States, in the North America region.

How does Vera Therapeutics make money?

One revenue line is on record: product Sales (pending approval).

Who are Vera Therapeutics's main competitors?

Direct peers on record are Travere Therapeutics, Calliditas Therapeutics, Otsuka Pharmaceutical, Chinook Therapeutics (Novartis) and Aurinia Pharmaceuticals. argenx is listed as an emerging player. Broad incumbents are Vertex Pharmaceuticals, Roche / Genentech, Bristol-Myers Squibb and AstraZeneca / Alexion.

Does Vera Therapeutics have an API?

No public API is recorded for Vera Therapeutics.

What industry is Vera Therapeutics in?

Vera Therapeutics's product category is Biologic Therapeutics for Autoimmune Kidney Disease. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StLearn Why The Bull Case For Vera Therapeutics Stock Could Change Following Wider Net LossesVera Therapeutics reported a Q3 2026 net loss of $93.71 million and a nine-month loss of $324.22 million, widening its cash burn. Analysts forecast revenue of $900.1 million and earnings of $137.4 million by 2029, but the loss highlights dependence on TRUTAKNA and BAFF/APRIL programs to offset expenses.Investing.comVera Therapeutics at Guggenheim conference: launch gains momentumVera Therapeutics reported at the Guggenheim conference that its IgA nephropathy drug TRUTAKNA has gained traction, with 700 Patient Start Forms in 17 weeks. The company estimates a $10-20 billion U.S. market and plans European filing in Q1 2025, with monthly dosing data expected this quarter.Defense WorldVera Therapeutics, Inc. $VERA Shares Sold by CenterBook Partners LPCenterBook Partners LP cut its Vera Therapeutics stake by 70.9% in Q3, selling 127,159 shares and holding 52,308 shares. The company reported Q3 EPS of -$1.30, beating the -$1.62 consensus, with revenue of $10.28 million. Analysts have a consensus price target of $74.93.American Banking and Market NewsVera Therapeutics, Inc. $VERA Stake Trimmed by CenterBook Partners LPCenterBook Partners LP trimmed its Vera Therapeutics stake by 70.9% in Q3, selling 127,159 shares and leaving with 52,308 shares valued at $1.69 million. Analysts rate the stock a Moderate Buy with a consensus price target of $74.93, while CEO Marshall Fordyce sold 18,500 shares.American Banking and Market NewsVera Therapeutics, Inc. $VERA Stock Acquired by Candriam S.C.A.Candriam S.C.A. increased its Vera Therapeutics stake by 21.5% in Q3, holding 568,560 shares. Vera reported Q3 2026 EPS of -$1.30, beating the -$1.62 consensus, with revenue of $10.28 million versus $3.42 million estimates. Analysts have an average price target of $74.93.Simply Wall StAnalysts Are Upgrading Vera Therapeutics, Inc. (NASDAQ:VERA) After Its Latest ResultsVera Therapeutics reported Q3 revenue of $10m, beating estimates by 209%, and a statutory loss of $1.30 per share, smaller than expected. Analysts upgraded 2027 revenue forecasts to $247.1m and losses to $3.93, but kept the price target at $73.00. The company is expected to grow revenue 12x annually by 2027, faster than the industry.American Banking and Market NewsVera Therapeutics (NASDAQ:VERA) Upgraded at Wall Street ZenWall Street Zen downgraded Vera Therapeutics from strong sell to sell, while other analysts gave mixed ratings. The company beat Q3 2026 EPS estimates at -$1.30 per share, with revenue of $10.28 million versus $3.42 million expected. The stock opened at $29.78.Stock TitanVera Therapeutics grants 14,900 inducement optionsVera Therapeutics granted inducement awards on November 2, 2026, to three new employees, including 14,900 stock options and 7,450 restricted stock units. The options have an exercise price of $30.25 and vest over four years, with RSUs vesting monthly thereafter.TradingViewWedbush maintains Vera Therapeutics at Neutral, lowers price target to $29 from $34Wedbush maintained Vera Therapeutics at Neutral and lowered its price target to $29 from $34, a 14.7% decrease. The target implies a 3.8% downside from the Nov 5 close of $30.14. Recent analyst price targets range from $34 to $75.Investing.comRaymond James raises Vera Therapeutics price target on strong launchRaymond James raised its price target on Vera Therapeutics to $87 from $84, keeping a Strong Buy rating after Q3 2026 earnings. The company reported $10.3 million in initial product revenue, exceeding the $5.1 million consensus, and patient start forms doubled to about 700. Vera is on track to reach 50% of covered lives by year-end 2026.